📊 CBIO Key Takeaways
Investment Thesis
Crescent BioPharma is a pre-revenue biotech company with severe operational losses and negative cash flow despite having substantial cash reserves. The company is burning capital at an unsustainable rate with operating expenses far exceeding minimal revenue, indicating immature or failed drug development programs with no clear path to profitability.
CBIO Strengths
- Strong liquidity position with $213.2M in cash and 6.56x current ratio, providing runway for operations
- Minimal debt burden with 0.00x debt-to-equity ratio, reducing financial distress risk
- Substantial equity cushion of $203.0M providing balance sheet stability
CBIO Risks
- Massive operating losses of -$152.6M with -1407.5% operating margin indicating failed or delayed drug development
- Severe negative cash flow of -$72.5M free cash flow annually will deplete cash reserves in ~3 years at current burn rate
- Near-zero revenue of $10.8M with no gross profit metrics suggests no viable commercial products or market traction
- Negative ROE of -75.8% and ROA of -64.1% demonstrate value destruction and inefficient capital deployment
- No insider buying activity in 90 days suggests lack of management confidence
Key Metrics to Watch
- Operating cash flow trend and runway remaining with current burn rate
- Revenue growth and pipeline advancement of drug candidates toward commercialization
- Operating expense management and path to operational profitability
- Cash position and potential need for dilutive financing
- Clinical trial progress and regulatory milestones for lead programs
CBIO Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 6.56x current ratio provides a solid financial cushion.
CBIO Profitability Ratios
CBIO vs Healthcare Sector
How CRESCENT BIOPHARMA, INC. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CBIO Balance Sheet & Liquidity
CBIO 5-Year Financial Trend
5-Year Trend Summary: CRESCENT BIOPHARMA, INC.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.58 indicates the company is currently unprofitable.
CBIO Growth Metrics (YoY)
CBIO Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2023 | $75.0K | -$8.3M | $-0.14 |
| Q2 2023 | $75.0K | -$8.3M | $-0.13 |
| Q3 2022 | $75.0K | -$8.5M | $-0.16 |
| Q2 2022 | $142 | -$13.3M | $-0.25 |
| Q1 2022 | $1.1M | -$14.3M | $-0.28 |
| Q3 2021 | $86.6K | -$7.7M | N/A |
| Q2 2021 | $142 | -$7.7M | N/A |
| Q1 2021 | $1.1M | -$7.7M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CBIO Capital Allocation
CBIO SEC Filings
Access official SEC EDGAR filings for CRESCENT BIOPHARMA, INC. (CIK: 0001253689)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CBIO
What is the AI rating for CBIO?
CRESCENT BIOPHARMA, INC. (CBIO) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CBIO's key strengths?
Strong liquidity position with $213.2M in cash and 6.56x current ratio, providing runway for operations. Minimal debt burden with 0.00x debt-to-equity ratio, reducing financial distress risk.
What are the risks of investing in CBIO?
Massive operating losses of -$152.6M with -1407.5% operating margin indicating failed or delayed drug development. Severe negative cash flow of -$72.5M free cash flow annually will deplete cash reserves in ~3 years at current burn rate.
What is CBIO's revenue and growth?
CRESCENT BIOPHARMA, INC. reported revenue of $10.8M.
Does CBIO pay dividends?
CRESCENT BIOPHARMA, INC. does not currently pay dividends.
Where can I find CBIO SEC filings?
Official SEC filings for CRESCENT BIOPHARMA, INC. (CIK: 0001253689) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CBIO's EPS?
CRESCENT BIOPHARMA, INC. has a diluted EPS of $-0.59.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.